Global Haemorrhagic Stroke Treatment Market Report and Forecast 2024-2032

Global Haemorrhagic Stroke Treatment Market Outlook

The global haemorrhagic stroke treatment market is expected to grow at a CAGR of 4.10% during the period 2024-2032. While rates of incidence of haemorrhagic stroke are heterogenous across the globe, Low and Middle Income countries (LMIC) such as those in Asia and Africa have been witnessing an upward trend.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Market Likely to be Driven by Cases of Stroke, Especially in Low and Middle Income Countries (LMIC)

While there is significant regional difference in incidence rates of haemorrhagic stroke, highest rates have been observed in LMIC regions such as sub-Saharan Africa and East Asia.

It is estimated that nearly 750,000 strokes take place in the USA every year. During a stroke, one or more regions in the brain may suffer damage, and an individual may experience loss of ability to move to one side of the body depending on the region affected. The damage may be permanent or temporary, and loss of function may be partial or full. Long-term outcome depends on the extent of brain damage, how quickly treatment starts, and several other factors.

Strokes may lead to long-lasting injury, disability, and even death. Early treatment and precautionary measures may decrease brain damage due to stroke. Treatment depends on stroke type (e.g. ischemic or haemorrhagic), the time since the first stroke symptoms appeared, and the individual’s underlying medical issues. Haemorrhage refers to bleeding. Haemorrhagic stroke takes place when blood vessels in the brain rupture or leak, leading to bleeding in or around the brain. It is estimated that nearly twenty percent strokes are haemorrhagic strokes. Damage may quickly occur because of pressure exerted by increasing amounts of blood or due to the blood itself. Blood irritates the brain tissue, and makes it swell. Bleeding around the brain is called subarachnoid haemorrhage (SAH), and is generally caused when an anomalous blood vessel (aneurysm) on the brain’s surface ruptures. Bleeding into the brain is known as intracerebral haemorrhage (ICH), and is generally caused by high blood pressure.

Treatments Options for Haemorrhagic Stroke Expected to Drive the Global Haemorrhagic Stroke Treatment Market

Treatment of haemorrhagic stroke depends on the cause of bleeding (e.g. anticoagulant medications, high blood pressure, trauma to the head, blood vessel malformation). Most patients need to be closely monitored in an ICU during and after a haemorrhagic stroke. Care for an individual suffering from haemorrhagic stroke includes identifying the cause of bleeding; regulating blood pressure; and stopping medication that could aggravate bleeding. A ventriculostomy tube is placed in the ventricle to measure pressure in the brain. If the pressure is high, some cerebrospinal fluid may be removed from the ventricle. A ventriculostomy may be employed to drain blood that has accumulated in the brain due to the stroke.

Treatments for haemorrhagic stroke include:

Surgical treatment — Surgery may be carried out to prevent or stop bleeding, or decrease pressure inside the skull. According to severity of stroke and the patient's condition, surgery may be performed within the first forty-eight to seventy-two hours after the haemorrhage; however, it may also be postponed to be done one to two weeks later to let the patient's condition stabilize.

Aneurysm treatment — An aneurysm refers to a blood vessel with a weak spot that protrudes out. If the area ruptures and bleeds, a haemorrhagic stroke could occur.

A clamp could be placed at the aneurysm’s base to prevent bleeding before a stroke or to stop rebleeding. The procedure entails removing a piece of the skull and tracing the aneurysm within the brain tissue; general anesthesia is generally employed and the procedure takes several hours. The piece of skull is replaced after the procedure.

Coil embolization is a procedure less invasive than clipping; it may be performed while the patient is sedated or put to sleep with the help of medicines. A flexible tube (catheter) is inserted into an artery in the groin, guided along blood vessels in the body into the brain vessel with the aneurysm. A minute coil is guided into aneurysm, filling the area with the coil. A blood clot is created within the coil, which blocks blood flow into the aneurysm and prevents it from rupturing again. Other materials may be injected to treat an aneurysm or arteriovenous malformation (AVM). New treatment systems employ stents (flow diverters) that reduce blood flow to the aneurysm.

Arteriovenous malformation treatment — Some AVMs carry a substantial risk of further bleeding. The decision to treat an AVM may depend on many factors, key factors being patient age, AVM location and size, vein abnormalities that drain the malformation, and whether the AVM has bled previously. Treatment could include surgery, radiosurgery, or embolization techniques.

Decompressive craniotomy — This procedure may be decided upon in cases where a patient's life seems threatened by pressure effects of a blood clot in the brain; it entails opening the skull and/or removing the blood. Considerations include size and location of haemorrhage, age and medical condition of patient, and the chances of recovery from the stroke.

Global Haemorrhagic Stroke Treatment Market Likely to be Driven by Demand for Medicines Used in Treatment

Medications for haemorrhagic stroke include:

• Beta Blockers, Alpha Activity.
• Vasodilators.
• Anticonvulsants, Other.
• Anticonvulsants, Hydantoins.
• Beta Blockers, Beta-1 Selective.
• Calcium Channel Blockers.
• Angiotensin Receptor Blockers.
• Angiotensin-converting Enzyme Inhibitors.

Market Segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

By type, the market is segmented into:

• Antihypertensive
• Anticoagulants
• Anticonvulsants
• Others

By distribution channel, the market is divided into:

• Hospitals Pharmacies
• Retail Pharmacies 
• Online Pharmacies

By region, the market is classified into:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Industry Players in the Global Haemorrhagic Stroke Treatment Market

The report presents a detailed analysis of the following key players in the market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• B. Braun Melsungen AG
• Medtronic
• Bayer AG
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report